On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Global stroke burden
- Thromboembolic occlusions and ischemic damage
- Possible interventions
- Consequences of low blood flow
- Recanalisation is associated with improvement
- Time is brain
- Where do thromboembolic occlusions originate?
- How can recanalisation be achieved?
- Pharmacological treatment
- Pharmacological treatment: alteplase
- Outcomes of alteplase treatment vs. placebo
- Importance of delay from stroke onset to treatment
- SITS-MOST
- Thrombolysis is safe and effective
- SITS-MOST univariate analysis results
- Door to needle time
- Treatment indications for intravenous rt-PA
- Comments on usual misunderstandings
- Treatment beyond European labelling
- Concern for haemorrhagic complications
- Risk factors for intracerebral haemorrhage (1)
- Risk factors for intracerebral haemorrhage (2)
- Recanalisation intervention beyond 3 hours
- Recanalisation strategies beyond i.v. thrombolysis
- HMCAS disappearance after i.v. thrombolysis
- HMCAS disappearance is important to outcome
- Thrombectomy using the MERCI device
- Example for the use of MERCI: background
- Example for the use of MERCI: the occlusion
- Example for the use of MERCI: the device location
- Example for the use of MERCI: recanalisation
- A clot on the MERCI device
- Combined iv thrombolysis- thrombectomy strategy
- Sonothrombolysis
- Possible hemorrhage and oedema complications
- Oedema complication
- Decompressive surgery
- Functional outcomes of decompressive surgery
- Risk reduction and odds ratio following surgery
- Eligibility criteria for the pooled analysis
- Exclusion criteria
- Thrombolysis for intracerebral haemorrhage
- New standards for organised stroke care
- Summary
- Thank you for your attention
Topics Covered
- Global stroke burden
- Neurological symptoms
- Where do thromboembolic occlusions originate?
- Recanalization
- Pharmacological treatment
- Clinical trials
- Treatment indications for intravenous rt-PA
- Common misunderstandings
- Treatment recommendations
- Haemorrhagic complications in routine clinical practice
- Multivariate analysis
- Risk factors
- Intravenous thrombolysis
- SITS
- Pooled analysis
- Thrombolysis and highly specialized interventions require new standards for organized stroke care
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Wahlgren, N. (2008, October 27). The treatment of stroke: specific management - thrombolysis plus [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/NAFG2782.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Nils Wahlgren has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.